Weight loss associated with semaglutide treatment among people with HIV.
AIDS
; 38(4): 531-535, 2024 Mar 15.
Article
em En
| MEDLINE
| ID: mdl-37976053
ABSTRACT
OBJECTIVE:
There is limited real-world evidence about the effectiveness of semaglutide for weight loss among people with HIV (PWH). We aimed to investigate weight change in a US cohort of PWH who initiated semaglutide treatment.DESIGN:
Observational study using the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort.METHODS:
We identified adult PWH who initiated semaglutide between 2018 and 2022 and with at least two weight measurements. The primary outcome was within-person bodyweight change in kilograms at 1âyear. The secondary outcome was within-person Hemoglobin A1c percentage (HbA1c) change. Both outcomes were estimated using multivariable linear mixed model.RESULTS:
In total, 222 new users of semaglutide met inclusion criteria. Mean follow-up was 1.1âyears. Approximately 75% of new semaglutide users were men, and at baseline, mean age was 53âyears [standard deviation (SD) 10], average weight was 108âkg (SD 23), mean BMI was 35.5âkg/m 2 , mean HbA1c was 7.7% and 77% had clinically recognized diabetes. At baseline, 97% were on ART and 89% were virally suppressed (viral load < 50âcopies/ml). In the adjusted mixed model analysis, treatment with semaglutide was associated with an average weight loss of 6.47âkg at 1âyear (95% CI -7.67 to -5.18) and with a reduction in HbA1c of 1.07% at 1âyear (95% CI -1.64 to -0.50) among the 157 PWH with a postindex HbA1c value.CONCLUSION:
Semaglutide was associated with significant weight loss and HbA1c reduction among PWH, comparable to results of previous studies from the general population.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Diabetes Mellitus Tipo 2
/
Peptídeos Semelhantes ao Glucagon
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
AIDS
Ano de publicação:
2024
Tipo de documento:
Article